Ferring Pharmaceuticals announces trade name Firmagon (degarelix) for advanced prostate cancer
FIRMAGON (degarelix injection) 80mg and 120mg vials of powder for reconstitution by Ferring
Ferring Pharmaceuticals announced the FDA has approved the trade name Firmagon (degarelix injection) for its prostate cancer treatment previously marketed under the generic name degarelix. Firmagon is an injectable gonadotropin-releasing hormone (GnRH) receptor antagonist that provides fast, long-term suppression of testosterone, a hormone that stimulates prostate cancer growth. It is available in 80mg and 120mg vials of powder for reconstitution.